New pill aims to stop chemo sickness in breast cancer patients

NCT ID NCT03386617

Ongoing Symptom relief Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a fixed-dose combination of netupitant and palonosetron (NEPA) to prevent nausea and vomiting in breast cancer patients receiving chemotherapy with adriamycin and cyclophosphamide. The trial includes 55 women in Hong Kong and tracks how well the drug works during the first 24 hours and up to 5 days after chemo. The goal is to improve comfort and reduce side effects during treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NEPA (netupitant and palonosetron)
What this could lead to: If it works, this could offer a more effective way to prevent nausea and vomiting during chemotherapy, improving patients' quality of life.
What could go wrong: This is a small, early-phase study with only 55 participants, so results may not apply to everyone. The drug may not work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Locations

Department of Clinical Oncology, Prince of Wales Hospital

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.